AXC-715 hydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1. AXC-715, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants.

Product information

CAS Number: 2490497-93-1

Molecular Weight: 347.89

Formula: C18H26ClN5

Chemical Name: 1-(4-aminobutyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine; chlorohydrogen

Smiles: Cl.CCCCC1=NC2=C(C3=CC=CC=C3N=C2N)N1CCCCN

InChiKey: ZTKBGQUHEQGVQH-UHFFFAOYSA-N

InChi: InChI=1S/C18H25N5.ClH/c1-2-3-10-15-22-16-17(23(15)12-7-6-11-19)13-8-4-5-9-14(13)21-18(16)20;/h4-5,8-9H,2-3,6-7,10-12,19H2,1H3,(H2,20,21);1H

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

References:

1. Sung-Ju Moon, et al. Compositions containing, methods and uses of antibody-tlr agonist conjugates. Patent WO2020168017A1
2. Shelley Erin ACKERMAN, et al. Immunoconjugates targeting pd-l1. Patent WO2020190734A1.

Products are for research use only. Not for human use.